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0022-2836/$ - see front matter © 2008 EThe X-ray crystal structures of covalent complexes of the Actinomadura R39
DD-peptidase and Escherichia coli penicillin-binding protein (PBP) 5 with β-
lactams bearing peptidoglycan-mimetic side chains have been determined.
The structure of the hydrolysis product of an analogous peptide bound
noncovalently to the former enzyme has also been obtained. The R39 DD-
peptidase structures reveal the presence of a specific binding site for the D-α-
aminopimelyl side chain, characteristic of the stem peptide of Actinomadura
R39. This binding site features a hydrophobic cleft for the pimelyl methylene
groups and strong hydrogen bonding to the polar terminus. Both of these
active site elements are provided by amino acid side chains from two
separate domains of the protein. In contrast, no clear electron density
corresponding to the terminus of the peptidoglycan-mimetic side chains is
present when these β-lactams are covalently bound to PBP5. There is,
therefore, no indication of a specific side-chain binding site in this enzyme.
These results are in agreement with those from kinetics studies published
earlier and support the general prediction made at the time of a direct
correlation between kinetics and structural evidence. The essential high-
molecular-mass PBPs have demonstrated, to date, no specific reactivity with
peptidoglycan-mimetic peptide substrates and β-lactam inhibitors and,
thus, probably do not possess a specific substrate-binding site of the type
demonstrated here with the R39 DD-peptidase. This striking deficiency may
represent a sophisticated defense mechanism against low-molecular-mass
substrate–analogue inhibitors/antibiotics; its discovery should focus new
inhibitor design.© 2008 Elsevier Ltd. All rights reserved.Keywords: penicillin-bindingproteins; DD-peptidases;β-lactam;peptidoglycan;
peptideEdited by G. SchulzIntroduction
Cell wall growth is integral to bacterial prolifera-
tion. The bacterial cell wall is composed of peptido-
glycan and grows by incorporation of disaccharide–
pentapeptide monomers. This occurs outside the cell
membrane and requires two kinds of enzyme active
site that separately catalyze transglycosylation and
transpeptidation reactions.1 The latter reaction servesess:
-binding protein.
lsevier Ltd. All rights reserveto stabilize the cell wall by crosslinking the glycan
strands. It is catalyzed by a class of enzymes knownas
D-alanyl-D-alanine transpeptidases (since they cata-
lyze the reaction of Scheme 1), or otherwise simply as
DD-peptidases, or, inasmuch as they are the targets of
β-lactam antibiotics, as penicillin-binding proteins
(PBPs).
As shown in Scheme 1, the DD-peptidases employ
an acyl-(serine)enzyme intermediate that can either
be aminolyzed (by R′NH2) to complete the peptido-
glycan crosslink or be hydrolyzed in a carboxypepti-
dase reaction to limit the extent of crosslinking. It
seems now quite well established that the essential
crosslinking reaction is catalyzed by a high-mole-d.
Scheme 1. The transpeptidase and carboxypeptidase reactions catalyzed by a DD-peptidase.
384 DD-Peptidase Structurescular-mass (60–100 kDa) group of DD-peptidases,
while a lower-molecular-mass (40–60 kDa) group
appears to have in vivo only DD-carboxypeptidase
and DD-endopeptidase activities.2,3 In vitro, how-
ever, several members of the latter group are also
able to catalyze transpeptidation reactions with
small peptides and esters.3,4 The enzymatic activity
of these enzymes has recently been reviewed.5
In view of their in vivo role as DD-peptidases, one
would anticipate that these enzymes would exhibit
substrate specificity towards peptides that areanalogous in structure to oligopeptide elements of
peptidoglycan. In certain instances, this appears to
be correct. For example, peptide 1 is a very specific
substrate of the low-molecular-mass DD-peptidase of
Streptomyces R61, which catalyzes both transpepti-
dase and carboxypeptidase reactions with this
substrate as acyl donor.6–8 In view of Streptomyces
peptidoglycan structure (peptide 2), this result is
logical, although it is striking that peptide 3, con-
taining another significant element of peptide 2, is a
poor substrate comparable to generic D-alanyl-D-
385DD-Peptidase Structuresalanine-terminating peptides.9 Aswould be expected
on the basis of these results, crystal structures show
that peptide 1 binds very snugly to the R61 DD-
peptidase active site, which contains what appears to
be a specific binding site for the glycyl-L-aminopime-
lyl moiety.10 β-Lactams with this same side chain
(e.g., peptide 4) are also extremely potent covalent
inhibitors of the R61 enzyme and employ the same
specific side-chain binding site.11,12
A survey of examples of the major classes of bac-
terial DD-peptidases, however, showed that the
above result is not general, at least with respect to
specificity in substrate turnover and β-lactam-inhi-
bitory kinetics.9,13 The high-molecular-mass en-
zymes, for example, do not show any particular
preference for peptidoglycan-mimetic peptides and
β-lactams analogous to peptides 1 and 3 or β-lactam
4, nor do certain low-molecular-mass enzymes (e.g.,
Escherichia coli PBP5 and Streptococcus pneumoniae
PBP3).9,13 On the basis of the R61 DD-peptidase result,
we predicted that the crystal structures of enzymes
that show kinetic specificity for peptidoglycan-
mimetic peptides and β-lactams will contain specific
binding sites for the side chains of these molecules,
whereas those that show no kinetic specificity will
not.13 To support these predictions,wedescribe in this
article the crystal structures of complexes of two low-
molecular-mass DD-peptidases with peptidoglycan-
mimetic ligands, the β-lactams 5 and 6, and the
peptide 7 bound to them. Kinetics studies showed
that the Actinomadura R39 DD-peptidase does display
peptidoglycan-mimetic substrate specificity analo-
gous to that of the R61 enzyme, but E. coli PBP5
does not.9,13
The Actinomadura R39 DD-peptidase is a low-mole-
cular-mass class C enzyme2 with strong amino acid
sequence similarity to E. coli PBP4 and Bacillus subtilis
PBP4a.14,15 Crystal structures have confirmed the
structural resemblance.16–18 TheR39 DD-peptidase is a
water-soluble enzyme that is loosely associated with
the bacterial cellmembrane. Although the precise role
of the enzyme in vivo is not known, under in vitro
conditions, it has been shown to catalyze the hydro-
lysis and aminolysis of small D-alanyl peptides and
esters.19,20
PBP5 of E. coli is also categorized as a low-molecu-
lar-mass PBP, but of class A.2 It is not essential to the
survival of E. coli, but its absence affects cell mor-
phology.21 Under normal conditions, it is apparently
responsible for much of the D-alanine carboxy-
peptidase activity that limits cell wall crosslinking.22
In vivo, PBP5 is attached to the E. coli inner mem-
brane by a C-terminal α-helix,23 removal of which
affords the solubilized protein used for kinetics
studies and crystal structure determination.24 The
solubilized construct is inhibited by β-lactams and
also catalyzes the hydrolysis and aminolysis of small
D-alanyl peptides and esters,25 although much less
efficiently than the R39 enzyme. The general orga-
nization of catalytic functional groups in PBP5 is
very similar to that in the R39 DD-peptidase, and
both resemble that of a class A β-lactamase;16
neither, however, contains an analogue of Glu166of the β-lactamase—the β-lactam deacylation cata-
lyst. Extensive structural details of the low-mole-
cular-mass PBPs are provided in a recent review.26
The crystal structures described in this article strong-
ly support the predictionsmade above in regard to DD-
peptidase substrate specificity: a specific side-chain




The asymmetric unit of R39 DD-peptidase crystals
contains four protein molecules that are not in the
same crystallographic environment.16 The environ-
ment is very similar for monomers A and D, and for
monomers B and C, but is different for both pairs.
In the R39/6 complex, all four monomers' active
sites are acylated by the ligand, and the conforma-
tion of the complex is the same in eachmonomer. The
electron density map calculated in the absence of
ligand provides a very clear density showing cepha-
losporin 6 covalently linked to the enzyme active
serine (Fig. 1a). The carbonyl oxygen lies in the
oxyanion hole, the carboxylate is oriented towards
the hydroxyl group of Thr411 (from the KTG motif),
and the amide group of the cephalosporin side chain
iswedged between the side chain ofAsn300 (from the
SXN motif) and the backbone of the strand that lines
the active site. In these features, the structure closely
resembles those generally found for complexes of
β-lactamswithβ-lactam-recognizing enzymes, inclu-
ding that of nitrocefin with the R39 DD-peptidase.16
Of particular interest to this article is the disposition
of the D-α-aminopimelyl side chain. The methylene
groups of the side chain are placed between the side
chains of Tyr157 and Met414, and the hydrophobic
environment is completed by the side chain of Leu349
in the rear of the active site. The side chain of Tyr157
essentially occupies the same position as in the free
enzyme; in the nitrocefin complex, it moves to pro-
vide hydrophobic cover to the thienyl side chain.16
The terminal H3N
+-CH-COO− moiety of the amino-
pimelic acid is inserted into a pocket composed of
residues Trp139 (π-cation), Asp142, Arg351, and
Ser415 (hydrogen bonds), with a salt bridge between
the aminopimelic acid carboxylate and Arg351. The
aminopimelyl ammonium–terminus hydrogen bonds
to the Asp142 side chain. It is striking that, as with B.
subtilis PBP4a,18 the elements of the side-chain bind-
ing site are derived from two separate domains of the
protein:16 the β-lactam-binding domain per se and
domain II, with the latter supplying Trp139, Asp142,
and Tyr147 (Fig. 1a).
In the complex of the enzyme with the peptide 7,
density maps reveal the presence of D-α-amino-ε-
pimelyl-D-alanine in monomers A, B, and C (Fig. 1b).
D-α-Amino-ε-pimelyl-D-alanine is one of the pro-
ducts of the carboxypeptidation reaction that is
catalyzed by the R39 DD-peptidase. Electron density
that could be attributed to the released D-alanine
386 DD-Peptidase Structures(the second product of the reaction) may also have
been observed, but we have attributed this electron
density to a sulfate ion as in the apostructure of the
R39 enzyme.16
The D-alanine carboxylate of D-α-amino-ε-pimelyl-
D-alanine is turned away from the active-site serine
as if it had rotated around the pimelyl ε-carbon–
peptide carbonyl bond after the deacylation. Awater
molecule is present in the oxyanion hole between the
active serine and the alanine carbonyl oxygen atoms.
Such a rotation was also observed in the complex of
the Streptomyces R61 DD-peptidase with a specific
peptide product,10 but in that case, the carboxylate
twisted into the protein, probably by rotation around
the D-alanyl α-carbon–peptide N bond, rather than
away from the protein as in the present case. Impor-
tantly, however, in the present structure, the D-α-
aminopimelyl side chain is positioned exactly like
the side chain of cephalosporin 6 in the β-lactam
complex described above.
The R39 DD-peptidase has a structural homology
that is close to that of the B. subtilis PBP4a, which
was previously crystallized and soaked with pep-
tide 7.18 The positions of the active-site residues of
both structures are nearly identical, and the side
chain of peptide 7 occupies exactly the same
position, making identical interactions, particularly
with Asp142 and Ser415 (R39 numbering); the one
notable difference is that Arg351 is replaced by a
histidine in PBP4a. In the primary structure of most
PBPs homologous to R39 (e.g., E. coli PBP4 and
Neisseria gonorrhoeae PBP3), this residue is a histidine
or an arginine, and the other residues forming the
meso-diaminopimelate-binding pocket are well con-
served. The hydrophobic cleft accommodating the
methylene chain is also conserved.
Although monomers A and D have very similar
crystallographic environments, the active site of
molecule D is not occupied by the ligand. The
Asn176 side chain of a symmetry mate inserts into
the pocket occupied by the aminopimelyl moiety in
the other monomers. In molecule A, the Asn176 side
chain (of a symmetric molecule) is clearly shifted,
and the pocket is occupied by the side chain of
peptide 7.
PBP5 structures
In the complex with cephalosporin 6, the acyl
linkage with Ser44 and most of the dihydrothiazine
ring are clearly defined in the electron density,
indicating that cephalosporin 6 has bound andFig. 1. Crystal structures of the R39 DD-peptidase in compl
crystal structures of PBP5 from E. coli in complex with (c) the ce
of the respective active sites, the electron density is a |Fo|−|F
each model refined in the absence of the ligand. The resulting
Carbon atoms of each ligand that are visible in the electron den
Those that could not be modeled (in PBP5) due to weak dens
positions of these groups. The carbon atoms of amino acids th
red, nitrogen atoms are in blue, and sulfur atoms are in orange
the distances are noted in angstroms. Some distances beyond
with the equivalent distances in (c). This figure was generatedreacted covalently with PBP5 (Fig. 1c). Weak density
is observed in the ring around C2. The C-3′ acetoxy
group is lost, as expected.12,29 Onmoving away from
this region, however, less of the molecule is visible.
Although some difference peaks that might corre-
spond to the terminal carboxylate and amino groups
of the D-α-amino-ε-pimelyl side chain are present
near residues Thr217, Asp41, and Leu153, the side
chain could not be modeled without ambiguity and
thus—extending from the aminopimelyl β-carbon—
is excluded from the model. Only a few hydrogen-
bonding interactions that involve the cephalosporin
are present; these hydrogen bonds (none is unex-
pected on the basis of previous structures of cephem
complexes) are between the cephem carboxylate and
the hydroxyl group of Thr214 and the side-chain
terminus of Arg248 (see below), between the side-
chain amide carbonyl and a side-chainNHofAsn112
and the backbone NH of Ser87, and between the
acyl–serine carbonyl and the oxyanion hole (NH of
His216 and Ser44). Neither Lys47Nζ nor Ser110Oγ is
within the hydrogen-bonding distance of Ser44 Oγ.
This disposition of the latter functional groups,
however, is commonly found in complexes of PBPs
with β-lactams and presumably reflects their cataly-
tic incompetence towards deacylation.
A similar picture is observed in the complex of PBP5
with the penicillin 5 (Fig. 1d). The acyl–serine linkage
and thiazolidine ring are both clearly visible, except
for weak density corresponding to one of the methyl
group substituents on the ring (C16). Some density
corresponding to the first part of the side chain is
visible, but it disappears from the aminopimelyl Cγ
onwards. Consequently, this region is not included in
the model. The enzyme appears to participate in only
three hydrogen bondswith the penicillin, between the
acyl–serine carbonyl in the oxyanion hole (NH of
His216 and Ser44) and between the side-chain amide
NH and the backbone carbonyl of His216. Notably
absent are interactions between the penam carbox-
ylate and the protein: the side chains of neither Thr214
nor Arg248 appear to make contact (cf. the cephalos-
porin structure described above).
The overall paucity of side-chain electron density
for both ligands is an interesting result and suggests
that, for PBP5, at least when organized within a
crystal lattice, the β-lactams 5 and 6 can acylate the
active-site serine, but beyond the region around the
covalent bond, these compounds make relatively few
contactswith the enzyme. There is certainly no sign of
a specific side-chain binding site as described above
for the R39 DD-peptidase. Indeed, this region isex with (a) the cephalosporin 6 and (b) the peptide 7, and
phalosporin 6 and (d) the penicillin 5. In these stereoviews
c| difference map calculated from the final coordinates of
positive density is shown in blue and is contoured at 2.0σ.
sity and have been included in the final model are in green.
ity are in gray and are included to show the approximate
at form each active site are in yellow. Oxygen atoms are in
. Potential hydrogen bonds are shown as dashed lines, and
hydrogen-bonding range are shown in (d) for comparison
using PYMOL (www.pymol.sourceforge.net).
387DD-Peptidase Structuresstructured quite differently in PBP5. When compared
to the R39 DD-peptidase structure, it comprises only
residues from the penicillin-binding domain, whereasFig. 1 (legend onthe R39 DD-peptidase includes residues from its
domain II, which has no counterpart in PBP5, to
bind the peptide terminus.previous page)
Fig. 2. Interaction between Arg248 and the cephalosporin carboxylate. The backbones of wild-type (green), penicillin-
5-bound (purple), and cephalosporin-6-bound (yellow) structures of PBP5 are superimposed, showing conformational
differences in a loop comprising residues 242–248. In the cephalosporin structure, Arg248 interacts with the carboxylate of
the cephalosporin (in yellow), whereas in the penicillin-bound structure, Arg248 occupies a position similar to that in
wild-type PBP5. There are also differences in the respective positions of Phe245. The figure was prepared using
MOLSCRIPT27 and Raster3D.28
388 DD-Peptidase StructuresComparison with wild-type PBP5
Both β-lactam-bound structures were compared
with that of the wild-type enzyme.30 All main-chain
atoms of the cephalosporin-6-bound structure could
be superimposed onto the wild-type structure with
an RMSD of 0.31 Å; the equivalent value for the
penicillin-5-bound structure was 0.40 Å. Examina-
tion of the superimposed backbones showed them to
be virtually indistinguishable, except for one region
comprising residues 242–248, inclusive. In the wild-
type enzyme, this region forms a distorted helical
region immediately preceding α10, which starts at
residue 249 (see Davies et al.31 for secondary struc-
ture assignments). In the cephalosporin-6-bound
structure, however, these residues adopt a more
canonical helical conformation such that α10 now
starts earlier at residue 245 (Fig. 2). A possible trigger
for this conformational change is the interaction
between Arg248 and the carboxylate of the cephalos-
porin. To make this interaction, the guanidinium
group of the arginine has shifted by approximately
6 Å,when compared to its position inwild-type PBP5.
This change in Arg248 appears to destabilize Phe245
because the side chain of this residue nowexists in two
(and possibly more) conformations. That the car-
boxylate of the cephalosporin interacts with Arg248 is
a little surprising, as we had postulated previously
that this group may interact with Arg198, which, in
wild-type PBP5, appears much better placed. In fact,the side chain of Arg198 is disordered in the Com-
pound-6-bound structure.
The same region is also slightly altered in the
penicillin-5-bound structure, but in this case, the
backbone is intermediate in position between wild-
type PBP5 and the cephalosporin-6-bound structure
(Fig. 2). Again, this region is characterized by
relatively weak density. Curiously, the side chain
of Arg248 does not interact with penicillin carbox-
ylate and occupies essentially the same position as in
the wild-type structure. Thus, there are differences
between the interactions with the protein made by
the cephalosporin and by the penicillin.
Of further interest, a conformational change that
occurred in a complex of PBP5 with a boronic acid
peptide mimetic—a shift in residues 152–154 near
the active site32—was not observed in either of the
ligand-bound structures presented here. Thus, it
appears that different compounds reacting with
PBP5 induce different and specific conformational
changes in the protein (see below).Discussion
The structures of complexes of the R39 DD-peptidase
with ligands 6 and 7, as described above, show very
clearly the presence of a specific binding site for the D-
aminopimelyl side chain (Fig. 1a and b). This result
therefore resembles that obtained for the Streptomyces
389DD-Peptidase StructuresR61 DD-peptidase where an analogous side-chain
binding site was observed, appropriate for the gly-
cyl-L-aminopimelyl moiety of Streptomyces peptido-
glycan.10 An analogous site is likely present on B.
subtilis PBP4a.18 In what appears to be sharp contrast,
essentially no firm electron density for the side chain,
and none particularly for the polar terminus, was ob-
served in the complexes of E. coli PBP5with β-lactams
5 and 6 (Fig. 1c and d). This suggests the absence of a
specific binding site for the N-terminus of the stem
peptide in this enzyme. It is possible that crystal
packing interactions may have led to this result with
PBP5, but there is certainly no overt indication of this
problem such as there is, for example, with monomer
D of the R39/peptide 7 complex (see above).
These results are strongly supported by kinetics
results. The peptide 7 is an excellent substrate of the
R39 DD-peptidase (kcat=7.4 s
−1; Km=1.3 μM; kcat/
Km=5.7×10
6 s−1 M−1)10; similarly, Compounds 5
and 6 are excellent inhibitors.13 These numbers mir-
ror those from the analogous peptidoglycan-mimetic
peptide 1 with the R61 DD-peptidase (kcat=69 s−1;
Km=7.9 μM; kcat/Km=8.7×10
6 s−1 M−1)6 and from
analogousβ-lactams.11,13 On the other hand, peptide
7 is a very poor substrate of the E. coli PBP5 (kcat/
Kmb50 s
−1 M−1), poorer indeed than the generic
peptide N,N′-diacetyl-L-lysyl-D-alanyl-D-alanine.25
The kinetics results published previously and the
structures presented here are thus in complete
agreement. It should also be noted here that neither
the R39 DD-peptidase nor E. coli PBP5 catalyzes
hydrolysis of the peptide 3 at rates suggestive of
specific interaction.9 No strong specificity for this
element of peptidoglycan structure has yet been de-
monstrated for any DD-peptidase.13
It seems likely, therefore, that the R39 DD-peptidase
has evolved to specifically accept an acyl donor sub-
strate containing the D-α-aminopimelyl side chain.
The lowKm and therefore high kcat/Kmvalues suggest
that the substrate is at low effective concentration in
vivo. The R39 DD-peptidase is known to catalyze
carboxypeptidation, transpeptidation, and endopep-
tidation reactions in vitro,19,20 although its substrate
specificity in the latter two reactions has not yet been
thoroughly explored. The role of the enzyme in vivo is
not known. It may even, as has also been suggested
for the Streptomyces R61 DD-peptidase,3,33 be a β-lac-
tam scavenger.
It should be noted, however, that other low-mole-
cular-mass class C enzymes that have structures very
similar to those of the R39 enzyme (e.g., E. coli PBP4
and B. subtilis PBP4a)14,17,18 do appear to have real, if
nonessential (in the same sense as E. coli PBP5
perhaps; see below), roles in bacterial cell wall cons-
truction and maintenance.34,35 The latter of these
enzymes has also been shown to have high hydro-
lytic activity against the peptide 7.18
There is no doubt that E. coli PBP5 does participate
in bacterial cell wall construction and/or mainte-
nance. Although it is not essential for cell survival and
reproduction, its absence does lead to aberrations in
cell shape21 and, presumably, a decrease in long-term
evolutionary fitness. The structures described aboveare in agreement with the kinetics results and strong-
ly suggest that no strong binding of peptidoglycan-
mimetic peptides occurs, to the solubilized enzyme at
least. This seems to be true of the membrane-bound
holoenzyme also, both in vivo and after isolation in
membranes.36 It may be that this enzyme recognizes
as its specific substrate a much larger segment of
peptidoglycan thanmimicked by the peptides used in
in vitro studies to date. The incorporation of mono-
saccharides and disaccharides in a complete pepti-
doglycanmonomer did not, however, yield enhanced
catalysis.37 Alternatively, as has been suggested from
time to time, in the two-dimensional milieu of the cell
membrane, where the substrate may be effectively
immobilized, a high affinity for the substrate may not
be required (i.e., sufficient affinity in vivo appears as
low affinity in three-dimensional in vitro solution
studies). The ease, or otherwise, of physical access of
these enzymes to their substrates in vivo is, of course,
an unknown factor.
S. pneumoniae PBP3 is another low-molecular-mass
class A enzyme that has been studied to some degree
both kinetically and structurally.38 It appears to be
more active in vitro than E. coli PBP5 (the kcat/Km for
N,N′-diacetyl-L-lysyl-D-alanyl-D-alanine hydrolysis
is 5700 s−1 M−1),38 but still has weak affinity for
peptide substrates (the Km for N,N′-diacetyl-L-lysyl-
D-alanyl-D-alanine is 19 mM; the value of this para-
meter for E. coli PBP5 is at least this high).25,39 This
higher activity may reflect the multiple layers of
peptidoglycan in Gram-positive bacteria. At any
event, it is possible that, even with a weakly specific
binding site and correspondingly highKmvalues, the
kcat values (e.g., N,N′-diacetyl-L-lysyl-D-alanyl-D-
alanine: for E. coli PBP5 in solution, kcatN0.2 s
−1;25,39
for S. pneumoniae PBP3, kcat=110 s
−138) may be large
enough for the in vivo role of these enzymes.
Under either of the above scenarios, the lack of
structural specificity towards smallmolecule substrates
is striking and may reflect a powerful defense against
small-molecule peptidoglycan-mimetic inhibitors.36
It is noticeable in the crystal structures of apo-PBP5
and those of its β-lactam complexes reported above
that the active site appears in a very open conforma-
tion, with the active-site residues being more spread
out than expected in an active conformation. Simple
measures of this are the Cα distances fromAsn112 or
Ser110 toGly215. Relevant data are shown in Table 1.
Striking from these data are the smaller distances
(narrower active-site cleft) in the more reactive S.
pneumoniae PBP3 and R39 DD-peptidase structures
than in PBP5, both alone and in its complexes with
β-lactams 5 and 6. Striking also are the smaller
distances in the PBP5–boronate inhibitor complex
where the boronate moiety is hydrogen-bonded to
the protein in the manner of a transition-state ana-
logue.32 The complexes of PBP5 with β-lactams 5
and 6 show no such tightening of the structure,
which might have been expected to accompany spe-
cific recognition. It may be that PBP5, in crystalline
form, in solution, and perhaps when resting in vivo,
relaxes to an open inactive conformation, unless
stimulated by a specific—and perhaps extended—
Table 1. Active-site distances in DD-peptidases
Enzyme/ligand
Distance (Å)
Asn Cα–Gly Cαa Ser Cα–Gly Cαa
E. coli PBP5 12.7 8.9
E. coli PB5/5 12.5 8.8
E. coli PBP5/6 12.4 8.7
E. coli PBP5/boronate 11.8 8.1
S. pneumoniae PBP3 11.6 8.3
R39 DD-peptidase 11.3 8.1
R39 DD-peptidase/6 10.8 7.8
R39 DD-peptidase/7 11.2 8.2
a These refer to the Asn and Ser residues of the SXN motif, and
to the Gly residue of the KXG motif of the respective enzymes.
390 DD-Peptidase Structuressubstrate. Such a phenomenon could explain its poor
reactivity with small substrates, including small pep-
tidoglycanmimetics such as peptide 7. S. pneumoniae
PBP3 is more reactive but still not specific for
elements of peptidoglycan that are local to the
reaction center.13 It may be that the two issues,
absolute reactivity and substrate specificity, are—
partly at least—separable.
The situation described above for E. coli PBP5 and
other low-molecular-mass class A enzymes is even
more complicated when the essential high-molecular-
mass enzymes are considered, where little, if any, DD-
peptidase activity and little affinity for peptidoglycan-
mimetic substrates and β-lactams have been demon-
strated in vitro.13 The issue of conformational changes
necessary for reactivity, both in crystalline form40,41
and in solution,42,43 has been raised for several of the
high-molecular-mass enzymes. As noted above, how-
ever, this may relate to absolute reactivity rather than
to substrate specificity. With respect to the latter, it
would not be surprising if the essential high-mole-
cular-mass DD-peptidases are even more assiduously
protected from small substrate–analogue inhibitors
than the low-molecular-mass enzymes. It might also
be noted here that essentially all PBP structures now
available, both free and complexed, display active-site
distances very similar to those of S. pneumoniae PBP3
in Table 1. Since these enzymes are certainly not all
equally reactive, with peptides for example, the latter
distances may be required for optimal activity, but are
certainly not sufficient. The exception is PBP2a of
Staphylococcus aureus, where the active-site gulf in the
crystal form is much narrower—a difference that has
been interpreted to reflect the very low reactivity of
this β-lactam-resistant enzyme.40
It is clear that much more needs to be done, both
structurally and kinetically, for us to understand,
qualitatively and quantitatively, how these enzymes
function in vivo. That they do function there, how-
ever, is even clearer—bacteria certainly flourish, for
better and for worse.Experimental Procedures
The β-lactams 5 and 6 and the peptide 7 were
obtained as previously described.9,13R39 DD-peptidase crystallography
The R39 DD-peptidase was expressed and purified
as described previously.44 The 538-amino-acid protein
precursor presents a 49-amino-acid N-terminal signal
peptide and, presumably, a 23-amino-acid C-terminal
extension that are both cleaved to yield a mature
soluble protein of 466 residues. Crystalsweregrownat
20 °C by hanging-drop vapor diffusion. The crystals
belong to the space group P21, with cell dimensions of
a=105.0 Å, b=93.3 Å, c=108.2 Å, and β=94.2°. The
crystallization medium contained protein [2.5 μl of
protein solution (18 mg ml−1), also containing 5 mM
MgCl2 and 20 mM Tris, pH 8], 2 μl of well solution
[2.0Mammoniumsulfate and0.1M2-(N-morpholino)
ethanesulfonic acid, pH 6], and 0.5 μl of 0.1 M CoCl2
solution. R39 DD-peptidase crystalswere transferred to
2 μl of well solution containing Compound 6 (80mM)
for 48 h to form the R39/6 complex, or to 2 μl of well
solution containing Compound 7 and D-Ala to final
concentrations of 23.4 mM and 900 mM, respectively,
for 47 h to form the R39/7 complex. X-ray diffraction
experiments were carried out under cryogenic condi-
tions (100 K) after transferring the crystals into 100%
glycerol. Data were collected with a Rigaku RU-200
rotating anode generator operating at 40 kV and
100 mA, and with a MarResearch Mar345 Imaging
Plate (λ=1.5418 Å). Intensities were indexed and inte-
grated using XDS.45 Data were scaled with SCALA of
the CCP4 program suite,46 and all corresponding
statistics are given in Table 2.
Using the structure of the apoenzyme, a first
round of rigid-body refinement was carried out
with REFMAC5.47 The resulting unbiased electron
density maps displayed in Coot48 unequivocally
showed cephalosporin 6 covalently bound to the
enzyme in all four monomers and peptide 7 in
three monomers. The structure of the R39 DD-
peptidase bound to cephalosporin 6 was refined to
2.4 Å, and the structure with peptide 7 was refined
to 2.25 Å. The statistics of refinement are summar-
ized in Table 2.
PBP5 crystallography
Soluble wild-type PBP5 protein was purified and
crystallized as described previously.30 These crystals
belong to the C2 space group and have cell dimen-
sions of a=109.4 Å, b=50.3 Å, c=84.5 Å, and
β=120.9°.30 Crystal soaking experiments were per-
formed by transferring crystals to stabilizing solu-
tions comprising 8% polyethylene glycol 400 and
50 mM Tris–HCl (pH 8.0) and containing β-lactam
5 or 6. Various concentrations of β-lactams 5 and 6
and soak times were tested. The crystals were then
cryoprotected by gradually increasing the con-
centration of glycerol (in the same solution) in 5%
increments up to 25% glycerol over a period of about
an hour. The degree of incorporation of each com-
pound was assessed by examination of the electron
density maps after collection of trial data sets using a
rotating anode generator (home X-ray source). The
final soaking condition for Compound 5was 13 mM
Table 2. Data collection and refinement statistics
Crystal R39/6 R39/7 PBP5/5 PBP5/6
Data collection
Molarity of soak (mM) 80.0 23.4 13.2 30
Time of soak (h) 48 47 1 18
Wavelength (Å) 1.5418 1.5418 1.5418 0.97934
Resolution range (Å)a 20–2.4 (2.53–2.4) 20–2.25 (2.37–2.25) 47.0–2.0 (2.07–2.00) 41–1.60 (1.66–1.60)
Number of unique reflections 81,439 99,513 25,433 51,428
Rmerge (%)
a,b 15.0 (59.6) 14.7 (60.8) 10.7 (30.5) 7.4 (41.4)
Redundancya 3.7 (3.7) 3.7 (3.5) 2.5 (2.4) 3.5 (2.5)
Completeness (%)a 99.8 (100) 99.1 (94.9) 94.3 (85.9) 97.3 (82.7)
〈I〉/〈σI〉a 9.6 (2.5) 9.7 (2.3) 6.8 (2.0) 25.7 (1.8)
Refinement
Resolution range 16–2.4 15.7–2.25 47.0–2.0 41–1.6
Number of protein atoms 13,576 13,549 2742 2738
Number of water molecules 496 600 188 266
Rcryst (%) 20.7 23.0 23.8 19.3
Rfree (%) 26.0 28.5 29.6 21.5
RMSD from ideal stereochemistry
Bond lengths (Å) 0.009 0.010 0.011 0.011
Bond angles (°) 1.22 1.28 1.40 1.29
B-factors
Mean B-factor (all atoms) (Å2) 28.9 26.4 28.0 21.3
Mean B-factor (main chain) (Å2) 28.7 26.2 27.4 18.9
RMSD in main-chain B-factors (Å2) 0.53 0.32 0.53 0.59
Mean B-factor (side chains and water
molecules) (Å2)
29.1 26.7 28.6 23.5
RMSD in side-chain B-factors (Å2) 1.19 0.70 1.13 1.40
Ramachandran plot
Most favored region (%) 88.4 90.0 92.2 92.5
Additionally allowed regions (%) 10.8 9.4 6.9 7.2
Generously allowed regions (%) 0.6 0.5 0.7 0.3
Disallowed regions (%) 0.1 0.1 0.3 0.0
RMSD of Cα atom with native structure (Å) 0.43c 0.48 0.40 0.31
a Statistics for the highest-resolution shell are given in parentheses.
b Rmerge=∑|Ii− Im|/∑Ii, where Ii is the intensity of the measured reflection and Im is the mean intensity of all symmetry-related
reflections. Figures within parentheses are for the outer-resolution shell.
c Monomer A.
391DD-Peptidase Structuresfor 1 h, and that for cephalosporin 6 was 30 mM for
18 h.
For the complexwith penicillin5, datawere collected
on an R-AXIS IV++ image plate detector mounted on
an RU-H3R rotating anode X-ray generator fittedwith
Osmic Confocal Optics (Rigaku MSC). Data (180°)
were collected and processed with d*Trek.49
Data for the complex with cephalosporin 6 were
collected at the SER-CAT ID22 beamline of the Ad-
vanced Photon Source on aMar 300 CCD detector at
a wavelength of 0.979 Å. The data were processed
using HKL2000.50
In both cases, the starting structure for refinement
was the structure of wild-type PBP5,30 but stripped
of water molecules and other ligands. After an initial
round of refinement, using CNS51 for cephalosporin
6 or using REFMAC547 for Compound 5, a differ-
ence electron density map (|Fobs|−|Fcalc|) was cal-
culated and displayed using the graphics program
O.52 The coordinates for each compound were
built in the Monomer Library Sketcher module of
REFMAC5 and manually positioned into the un-
biased positive electron density in the active site of
the enzyme using O. Thereinafter, each model was
refined using REFMAC5, alternating with rounds of
manual revision. A subset (5%) of the reflections was
set aside for calculation of the free R-factor.53 Watermolecules with reasonable hydrogen bond distances
were included in later rounds of refinement, and
several amino acid side chains were modeled with
multiple conformations. The stereochemistries of the
final models were evaluated using PROCHECK.54
The structure, in complex with the cephalosporin 6,
was refined to 1.6 Å resolution with an R-factor of
21.2% and an Rfree of 23.5%, and that with the
penicillin 5 was refined at 2.0 Å with an R-factor of
23.8% and an Rfree of 29.6%. Both structures have
excellent stereochemistry (see Table 2).
Protein Data Bank accession codes
The atomic coordinates for the crystal structures
described above have been deposited in the RCSB
Protein Data Bank and are available under accession
codes 2VGJ (R39/6 complex), 2VGK (R39/7 com-
plex), 3BEB (PBP5/5), and 3BEC (PBP5/6 complex).Acknowledgements
Use of the Advanced Photon Source for the PBP5
project (A.J.P., J.H., and C.D.) was supported by the
392 DD-Peptidase StructuresUS Department of Energy, Office of Science, Office
of Basic Energy Sciences, under contract no. W-31-
109-ENG-38. Data were collected at the Southeast
Regional Collaborative Access Team BM22 beamline
at the Advanced Photon Source, Argonne National
Laboratory. Supporting institutions may be found at
www.ser-cat.org/members.html. The X-ray crystal-
lography facility used for the PBP5 work was
supported by the Medical University of South
Carolina's Research Resource Facilities program.
The R39 project (E.S. and P.C.) was supported, in
part, by European Commission Sixth Framework
Program grants LSMH-CT-COBRA 2003-503335 and
LSMH-CT-EUR-INTAFAR 2004-512138; by the Bel-
gian Program on Interuniversity Poles of Attraction
initiated by the Belgian State, Prime Minister's Office,
Science Policy programming (IAP no. P6/19); by the
Actions de Recherche Concertées (grant 03/08-297);
by the Fonds National de la Recherche Scientifique
(IISN 4.4505.00, FRFC 9.45/9.99, FRFC 2.4.508.01.F,
FRFC 9.4.538.03.F, and FRFC 2.4.524.03); and by the
University of Liège (Fonds spéciaux, Crédit classique,
1999). This research was also supported by National
Institutes of Health grants AI-17986 (R.F.P.) and GM-
66861 (C.D.).
Author Contributions
ES and PC carried out the crystallographic
analyses on R39. AJP, JH and CD carried out the
crystallographic analyses on PBP5. HRJ and RFP
performed the syntheses and kinetics analysis. ES,
CD and RFP wrote the paper.References
1. Macheboeuf, P., Contreras-Martell, C., Job, V., Dideberg,
O. & Dessen, A. (2006). Penicillin-binding proteins: key
players in bacterial cell cycle and drug resistance
processes. FEMS Microbiol. Rev. 30, 673–691.
2. Ghuysen, J.-M. (1991). Serine β-lactamases and peni-
cillin-binding proteins. Annu. Rev. Microbiol. 45, 37–67.
3. Goffin, C. & Ghuysen, J.-M. (2002). Biochemistry and
comparative genomics of SxxK superfamily acyltransfe-
rases offer a clue to themycobacterial paradox: presence
of penicillin-susceptible target proteins versus lack of
efficiency of penicillin as a therapeutic agent. Microbiol.
Mol. Biol. Rev. 66, 702–738.
4. Ghuysen, J.-M., Frère, J.-M., Leyh-Bouille, M., Coyette,
J., Dusart, J. & Nguyen-Distèche, M. (1979). Use of
model enzymes in the determination of the mode of
action of penicillins andΔ3-cephalosporins.Annu. Rev.
Biochem. 48, 73–101.
5. Pratt, R. F. (2008). Substrate specificity of bacterial DD-
peptidases (penicillin-binding proteins). Cell. Mol. Life
Sci., in press (DOI 10.1007/s00018-008-7591-7).
6. Anderson, J. W. & Pratt, R. F. (2000). Dipeptide bind-
ing to the extended active site of the Streptomyces R61
D-alanyl-D-alanine peptidase: the path to a specific
substrate. Biochemistry, 39, 12200–12209.
7. Kumar, I. & Pratt, R. F. (2005). Transpeptidation reac-
tions of a specific substrate catalyzed by theStreptomyces
R61 DD-peptidase: characterization of a chromogenic
substrate and acyl acceptor. Biochemistry, 44, 9971–9979.8. Kumar, I. & Pratt, R. F. (2005). Transpeptidation reac-
tions of a specific substrate catalyzed by the Strepto-
myces R61 DD-peptidase: the structural basis of acyl
acceptor specificity. Biochemistry, 44, 9961–9970.
9. Anderson, J. W., Adediran, S. A., Charlier, P., Nguyen-
Distèche, M., Frère, J.-M., Nicholas, R. A. & Pratt, R. F.
(2003). On the substrate specificity of bacterial DD-
peptidases: evidence from two series of peptidogly-
can-mimetic peptides. Biochem. J. 373, 949–955.
10. McDonough, M. A., Anderson, J. W., Silvaggi, N. R.,
Pratt, R. F., Knox, J. R. &Kelly, J. A. (2002). Structures of
two kinetic intermediates reveal species specificity of
penicillin-binding proteins. J. Mol. Biol. 322, 111–122.
11. Josephine, H. R., Kumar, I. & Pratt, R. F. (2004). The
perfect penicillin? Inhibition of a bacterial DD-pepti-
dase by peptidoglycan-mimetic β-lactams. J. Am.
Chem. Soc. 126, 8122–8123.
12. Silvaggi, N., Josephine, H. R., Kuzin, A. P., Nagarajan,
R., Pratt, R. F. & Kelly, J. A. (2005). Crystal structures of
complexes between the R61 DD-peptidase and pepti-
doglycan-mimetic β-lactams: a non-covalent complex
with a “perfect penicillin”. J. Mol. Biol. 345, 521–533.
13. Josephine, H. R., Charlier, P., Davies, C., Nicholas,
R. A. & Pratt, R. F. (2006). Reactivity of penicillin-
binding proteins with peptidoglycan-mimetic β-lac-
tams: what's wrong with these enzymes? Biochem-
istry, 45, 15873–15883.
14. Granier, B., Duez, C., Lepage, S., Englebert, S., Dusart,
J., Dideberg, O. et al. (1992). Primary and predicted
secondary structures of the Actinomadura R39 extracel-
lular DD-peptidase, a penicillin-binding protein (PBP)
related to Escherichia coli PBP4. Biochem. J. 282, 781–788.
15. Duez, C., Vanhove, M., Gallet, X., Bouillenne, F.,
Docquier, J.-D., Brans, A. & Frère, J.-M. (2001). Purifica-
tion and characterization of PBP4a, a new low-
molecular-weight penicillin-binding protein from Bacil-
lus subtilis. J. Bacteriol. 183, 1595–1599.
16. Sauvage, E., Herman, R., Petrella, S., Duez, C.,
Bouillenne, F., Frère, J.-M. & Charlier, P. (2005). Crystal
structure of the Actinomadura R39 DD-peptidase reveals
new domains in penicillin-binding proteins. J. Biol.
Chem. 280, 31249–31256.
17. Kishida, H., Unzai, S., Roper, D. I., Lloyd, A., Park,
S.-Y. & Tame, J. R. H. (2006). Crystal structure of
penicillin-binding protein 4 (dacB) from Escherichia
coli, both in the native form and covalently linked to
various antibiotics. Biochemistry, 45, 783–792.
18. Sauvage, E., Duez, C., Herman, R., Kerff, F., Perrella, S.,
Anderson, J. W. et al. (2007). Crystal structure of the
Bacillus subtilis penicillin-binding protein 4a, and its
complex with a peptidoglycan-mimetic peptide. J. Mol.
Biol. 371, 528–539.
19. Ghuysen, J.-M., Leyh-Bouille, M., Campbell, J. N.,
Moreno, R., Frère, J.-M., Duez, C. et al. (1973).
Structure of the wall peptidoglycan of Streptomyces
R39 and the specificity profile of its exocellular DD-
carboxypeptidase–transpeptidase for peptide accep-
tors. Biochemistry, 12, 1243–1251.
20. Zhao,G.-H.,Duez, C., Lepage, S., Forceille, C., Rhazi,N.,
Klein, D. et al. (1997). Site-directed mutagenesis of the
Actinomadura R39 DD-peptidase. Biochem J. 327, 377–381.
21. Nelson, D. E. & Young, K. D. (2000). Penicillin-binding
protein 5 affects cell diameter, contour and morpholo-
gy of Escherichia coli. J. Bacteriol. 182, 1714–1721.
22. Matsuhashi, M., Tamaki, S., Curtis, S. J. & Strominger,
J. L. (1979). Mutational evidence for identity of
penicillin-binding protein 5 in Escherichia coli with
the major D-alanine carboxypeptidase IA activity. J.
Bacteriol. 137, 644–647.
393DD-Peptidase Structures23. Harris, F., Brandenburg, K., Seydel, U. & Phoenix, D.
(2002). Investigations into the mechanisms used by
the C-terminal anchors of Escherichia coli penicillin-
binding proteins 4, 5, 6 and 6b for membrane
interactions. Eur. J. Biochem. 269, 5821–5829.
24. Nicholas, R. A., Krings, S., Tomberg, J., Nicola, G. &
Davies, C. (2003). Crystal structure of wild-type peni-
cillin-binding protein 5 from Escherichia coli. J. Biol.
Chem. 278, 644–647.
25. Stefanova, M. E., Davies, C., Nicholas, R. A. &Gutheil,
W. G. (2002). pH, inhibitor and substrate specificity
studies on Escherichia coli penicillin-binding protein 5.
Biochim. Biophys. Acta, 1597, 292–300.
26. Sauvage, E., Kerff, F., Terrak,M., Ayala, J. A. &Charlier,
P. (2008). The penicillin-binding proteins: structure and
role in peptidoglycan biosynthesis. FEMS Microbiol.
Rev. 32, 234–258.
27. Kraulis, P. J. (1991). MOLSCRIPT: a program to pro-
duce both detailed and schematic plots of protein
structures. J. Appl. Crystallogr. 24, 946–950.
28. Merritt, E. A. & Murphy, M. E. P. (1994). Raster3D
version 2.0. A program for photorealistic molecular
graphics. Acta Crystallogr. Sect. D, 50, 869–873.
29. Faraci, W. S. & Pratt, R. F. (1986). Interactions of ce-
phalosporins with the Streptomyces R61 DD-transpepti-
dase/carboxypeptidase. Influence of the 3′-substituent.
Biochem. J. 238, 309–312.
30. Nicholas, R. A., Krings, S., Tomberg, J., Nicola, G. &
Davies, C. (2003). Crystal structure of wild-type
penicillin binding protein 5 from E. coli: implications
for deacylation of the acyl–enzyme complex. J. Biol.
Chem. 278, 52826–52833.
31. Davies, C., White, S. W. & Nicholas, R. A. (2001).
Crystal structure of a deacylation-defective mutant of
penicillin-binding protein 5 at 2.3 Å resolution. J. Biol.
Chem. 276, 616–623.
32. Nicola, G., Peddi, S., Stefanova, M., Nicholas, R. A.,
Gutheil, W. G. & Davies, C. (2005). Crystal structure of
Escherichia coli penicillin-binding protein 5 bound to a
tripeptide boronic acid inhibitor: a role for Ser-110 in
deacylation. Biochemistry, 44, 8207–8217.
33. Kelly, J. A., Dideberg,O., Charlier, P.,Wery, J. P., Libert,
M.,Moews, P. C. et al. (1986). On the origin of bacterial-
resistance to penicillin—comparison of a beta-lacta-
mase and a penicillin target. Science, 231, 1429–1431.
34. Priyadarshini, R., Popham, D. L. & Young, K. D.
(2006). Daughter cell separation by penicillin-binding
proteins and peptidoglycan amidases in Escherichia
coli. J. Bacteriol. 188, 5345–5355.
35. Scheffers, D.-J., Jones, L. J. & Errington, J. (2004). Several
distinct localization patterns for penicillin-binding
proteins in Bacillus subtilis.Mol. Microbiol. 51, 749–764.
36. Kumar, I., Josephine, H. R. & Pratt, R. F. (2007).
Reactions of peptidoglycan-mimetic β-lactams with
penicillin-binding proteins in vivo and in membranes.
ACS Chem. Biol. 2, 620–624.
37. Hesek, D., Suvarov, M., Morio, K., Lee, M., Brown, S.,
Vakulenko, S. B. &Mobashery, S. (2004). Synthetic pep-
tidoglycan substrates for penicillin-binding proteins of
Gram-negative bacteria. J. Org. Chem. 69, 778–784.
38. Morlot, C., Pernot, L., LeGouellec, A., Di Giulmi, A.M.,
Vernet, T., Dideberg, O. & Dessen, A. (2005). Crystal
structures of a peptidoglycan synthesis regulatory
factor (PBP3) from Streptococcus pneumoniae. J. Biol.
Chem. 280, 15984–15991.39. Zhang, W., Shi, Q., Meroueh, S. O., Vakulenko, S. B. &
Mobashery, S. (2007). Catalytic mechanism of peni-
cillin-binding protein 5 of Escherichia coli. Biochemistry,
46, 10113–10121.
40. Lim, D. & Strynadka, N. C. J. (2002). Structural basis
for the β-lactam resistance of PBP 2a from methicillin-
resistant Staphylococcus aureus. Nat. Struct. Biol. 9,
870–876.
41. Macheboeuf, P., Di Giulmi, A. M., Job, V., Vernet, T.,
Dideberg, O. & Dessen, A. (2005). Active site
restructuring regulates ligand recognition in class A
penicillin-binding proteins. Proc. Natl Acad. Sci. USA,
102, 577–582.
42. Fuda, C., Hesek, D., Lee, M., Morio, K.-I., Nowak, T. &
Mobashery, S. (2005). Activation for catalysis of
penicillin-binding protein 2a from methicillin-resis-
tant Staphylococcus aureus by bacterial cell wall. J. Am.
Chem. Soc. 127, 2056–2057.
43. Fuda, C., Hesek, D., Lee, M., Heilmayer, W., Novak,
R., Vakulenko, S. B. et al. (2006). Mechanistic basis for
the action of new cephalosporin antibiotics effective
against methicillin- and vancomycin-resistant Staphy-
lococcus aureus. J. Biol. Chem. 281, 10035–10041.
44. Granier, B., Duez, C., Lepage, S., Englebert, S.,
Dusart, J., Dideberg, O. et al. (1992). Primary and
predicted secondary structures of the Actinomadura
R39 extracellular DD-peptidase, a penicillin-binding
protein (PBP) related to the Escherichia coli PBP4.
Biochem. J. 282, 781–788.
45. Kabsch, W. (1993). Automatic processing of rotation
diffraction data from crystals of initially unknown
symmetry and cell constants. J. Appl. Crystallogr. 26,
795–800.
46. CCP4 (1994). The CCP4 suite: programs for protein
crystallography. Acta Crystallogr. Sect. D, 50, 760–763.
47. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997).
Refinement of macromolecular structures by the
maximum-likelihood method. Acta Crystallogr. Sect.
D, 53, 240–255.
48. Emsley, P. & Cowtan, K. (2004). Coot: model-building
tools for molecular graphics. Acta Crystallogr. Sect. D,
60, 2126–2132.
49. Pflugrath, J. W. (1999). The finer things in X-ray dif-
fraction data collection. Acta Crystallogr. Sect. D, 55,
1718–1725.
50. Otwinowski, Z. & Minor, W. (1997). Processing of
X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 276, 307–326.
51. Brünger, A. T., Adams, P. D., Clore, G. M., De Lano,
W. L., Gros, P., Grosse-Kunstleve, R. W. et al. (1998).
Crystallography and NMR system: a new software
suite for macromolecular structure determination.
Acta Crystallogr. Sect. D, 54, 905–921.
52. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard,
M. (1991). Improved methods for building protein
structures in electron-density maps and the location
of errors in these models. Acta Crystallogr. Sect. A,
47, 110–119.
53. Brünger, A. T. (1992). Free R value: a novel statistical
quantity for assessing the accuracy of crystal struc-
tures. Nature, 355, 472–474.
54. Laskowski, R. A., MacArthur, M. W., Moss, D. S. &
Thornton, J. M. (1993). PROCHECK: a program to
check the stereochemical quality of protein structures.
J. Appl. Crystallogr. 26, 283–291.
